Consolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After Neoadjuvant Concurrent Chemoradiotherapy

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

358

Participants

Timeline

Start Date

December 7, 2016

Primary Completion Date

July 15, 2023

Study Completion Date

June 30, 2026

Conditions
Rectal Cancer
Interventions
DRUG

Chemotherapy

5-FU, Leucovorin, and Oxaliplatin (FOLFOX regimen)

Trial Locations (14)

11765

Uijeongbu St. Mary's Hospital, The Catholic University College of Medicine, Uijeongbu-si

16499

Ajou University School of Medicine, Suwon

24253

Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon

26426

Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wŏnju

31151

Soonchunhyang University Cheonan Hospital, Cheonan

35015

Chungnam National University Hospital, Daejeon

41931

Keimyung University Dongsan Medical Center, Daegu

47392

Inje University Busan Paik hospital, Busan

50612

Pusan National University Yangsan Hospital, Yangsan

54538

Wonkwang University Hospital, Iksan

58128

Chonnam National University Hwasun Hospital, Hwasun

01757

Inje University Sanggye Paik Hospital, Seoul

06273

Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul

06591

Seoul St. Mary's Hospital, The Catholic University College of Medicine, Seoul

All Listed Sponsors
collaborator

Korean Society of ColoProctology

UNKNOWN

collaborator

Pharmbio Korea Inc.

UNKNOWN

collaborator

Samjin Pharmaceutical Co., Ltd.

INDUSTRY

collaborator

Boryung Pharmaceutical Co., Ltd

INDUSTRY

collaborator

JW Pharmaceutical

INDUSTRY

lead

Kyung Hee University Hospital at Gangdong

OTHER